Press

Bobby Hand, DPT, Movement Disorders Program Coordinator at Virginia Commonwealth University Health in Richmond, VA, will present physical therapy techniques for persons diagnosed with progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA) during a webinar on Wednesday, February 24, 2021. Hosted by CurePSP, the 60-minute program begins at 2:00 p.m. Eastern Standard Time (11:00…

The Penn FTD Center is hosting a virtual conference for persons affected by frontotemporal degeneration (FTD) and amyotrophic lateral sclerosis (ALS) on Saturday, February 27, 2021. “Fighting for the Future: Education and Support for Familial FTD/ALS” will be held from 9:00 a.m. until 12:00 p.m. Eastern time (6:00 to 9:00 a.m. Pacific Time). The conference will address…

This February The Association for Frontotemporal Degeneration is marking the 10th anniversary of its With Love campaign.

The coronavirus COVID-19 vaccine and progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and multiple system atrophy (MSA) will be the topic during a webinar on Monday, January 25, 2021. Dr. Lawrence I. Golbe, Director of Clinical Affairs for CurePSP, will be the presenter at this 30-minute webinar that begins at 2:00 p.m. Eastern Standard Time…

Take the survey, watch the live stream, have your FTD voice heard!

The FTD Disorders Registry and The Association for Frontotemporal Degeneration (AFTD) have developed a partnership to present educational webinars for the FTD community called “Perspectives in FTD Research.” “AFTD and the Registry share the aim of educating the community about research and connecting people with opportunities to participate,” noted Dianna Wheaton, M.S., Ph.D., CHES, director…

The PROCLAIM study, sponsored by Prevail Therapeutics, is evaluating safety and effectiveness of a one-time investigational gene therapy (PR006) intended to treat people diagnosed with a form of frontotemporal degeneration caused by mutations in the progranulin gene (GRN), referred to as FTD-GRN. This Phase 1/2 clinical trial will also examine the effects of PR006 on progranulin protein levels in the plasma (the liquid…

The FTD Disorders Registry (FTDDR) has announced the release of its first Strategic Plan.

On Tuesday, December 15, 2020, Miriam Sklerov, M.D., M.S., movement disorders specialty neurologist at the University of North Carolina School of Medicine, will discuss how telemedicine in the age of COVID affects people with multiple system atrophy (MSA). This CurePSP Ask the Doctor webinar begins at 1:00 p.m. Eastern Standard Time (10:00 a.m. Pacific). Traveling to…

Watch the webinar!